Healthcare provider profile · identity verified

Robert M Altenau, MD

Family Practice · CINCINNATI, OH · NPI 1265674576

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	1095	356
Lisinopril	Lisinopril	273	98
Amlodipine Besylate	Amlodipine Besylate	259	89
Omeprazole	Omeprazole	248	90
Levothyroxine Sodium	Levothyroxine Sodium	217	78
Losartan Potassium	Losartan Potassium	204	70
Prednisone	Prednisone	201	149
Metformin Hcl	Metformin Hcl	196	76
Albuterol Sulfate Hfa	Albuterol Sulfate	165	55
Metformin Hcl Er	Metformin Hcl	162	50
Gabapentin	Gabapentin	158	56
Pantoprazole Sodium	Pantoprazole Sodium	148	50
Simvastatin	Simvastatin	134	47
Tamsulosin Hcl	Tamsulosin Hcl	134	56
Alendronate Sodium	Alendronate Sodium	132	42
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	132	45
Duloxetine Hcl	Duloxetine Hcl	131	52
Rosuvastatin Calcium	Rosuvastatin Calcium	131	48
Metoprolol Succinate	Metoprolol Succinate	115	43
Bupropion Xl	Bupropion Hcl	108	32
Finasteride	Finasteride	96	35
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	91	28
Jardiance	Empagliflozin	88	21
Eliquis	Apixaban	80	22
Pravastatin Sodium	Pravastatin Sodium	79	26
Allopurinol	Allopurinol	77	28
Methocarbamol	Methocarbamol	75	42
Trulicity	Dulaglutide	73	14
Trazodone Hcl	Trazodone Hcl	69	27
Montelukast Sodium	Montelukast Sodium	63	20
Carvedilol	Carvedilol	58	20
Hydrochlorothiazide	Hydrochlorothiazide	55	28
Metoprolol Tartrate	Metoprolol Tartrate	55	21
Sertraline Hcl	Sertraline Hcl	55	21
Spironolactone	Spironolactone	55	20
Pioglitazone Hcl	Pioglitazone Hcl	54	19
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	53	21
Amitriptyline Hcl	Amitriptyline Hcl	52	14
Fluoxetine Hcl	Fluoxetine Hcl	52	16
Ozempic	Semaglutide	51	15
Xarelto	Rivaroxaban	49	11
Atenolol	Atenolol	43	15
Meloxicam	Meloxicam	42	27
Hydroxyzine Hcl	Hydroxyzine Hcl	39	17
Ezetimibe	Ezetimibe	37	15
Fluticasone Propionate	Fluticasone Propionate	35	14
Furosemide	Furosemide	34	16
Ondansetron Hcl	Ondansetron Hcl	34	22
Escitalopram Oxalate	Escitalopram Oxalate	33	13
Januvia	Sitagliptin Phosphate	33	suppressed
Potassium Chloride	Potassium Chloride	32	12
Synthroid	Levothyroxine Sodium	32	11
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	31	suppressed
Lovastatin	Lovastatin	29	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	28	26
Mounjaro	Tirzepatide	28	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	28	suppressed
Citalopram Hbr	Citalopram Hydrobromide	26	suppressed
Calcitriol	Calcitriol	25	suppressed
Paroxetine Hcl	Paroxetine Hcl	25	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	25	suppressed
Warfarin Sodium	Warfarin Sodium	25	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	24	suppressed
Famotidine	Famotidine	23	suppressed
Pregabalin	Pregabalin	23	suppressed
Valsartan	Valsartan	23	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	22	18
Breo Ellipta	Fluticasone/Vilanterol	21	suppressed
Cefuroxime	Cefuroxime Axetil	21	16
Clopidogrel	Clopidogrel Bisulfate	21	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	21	19
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	20	suppressed
Donepezil Hcl	Donepezil Hcl	20	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	20	suppressed
Propranolol Hcl	Propranolol Hcl	20	suppressed
Buspirone Hcl	Buspirone Hcl	19	suppressed
Pen Needle	Pen Needle, Diabetic	19	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	18	suppressed
Nifedipine Er	Nifedipine	17	11
Oxybutynin Chloride Er	Oxybutynin Chloride	17	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	17	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	17	suppressed
Alprazolam	Alprazolam	16	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	16	suppressed
Benazepril Hcl	Benazepril Hcl	16	suppressed
Memantine Hcl	Memantine Hcl	16	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	16	16
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	16	suppressed
Verapamil Er	Verapamil Hcl	16	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	15	suppressed
Solifenacin Succinate	Solifenacin Succinate	15	suppressed
Tizanidine Hcl	Tizanidine Hcl	15	suppressed
Tresiba Flextouch U-100	Insulin Degludec	15	suppressed
Valacyclovir	Valacyclovir Hcl	15	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	15	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	14	suppressed
Linzess	Linaclotide	14	suppressed
Diclofenac Sodium	Diclofenac Sodium	13	suppressed
Droplet Pen Needle	Pen Needle, Diabetic	13	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	13	suppressed
Glimepiride	Glimepiride	13	suppressed
Hydralazine Hcl	Hydralazine Hcl	13	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	13	suppressed
Ramipril	Ramipril	13	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	13	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	13	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	12	suppressed
Ropinirole Hcl	Ropinirole Hcl	12	suppressed
Ciclopirox	Ciclopirox	11	suppressed
Mirtazapine	Mirtazapine	11	suppressed
Soliqua 100-33	Insulin Glargine/Lixisenatide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error